Dr. Finn on Current and Emerging Agents in the Field of HCC

Video

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, shares insight on some current and emerging agents in the field of hepatocellular carcinoma (HCC).

The field has recently seen promising data and an FDA approval of regorafenib (Stivarga) in the second-line setting of HCC treatment, Finn explains. At the 2017 International Liver Cancer Association Annual Conference, updated overall survival (OS) data on the phase III RESORCE trial, which compared regorafenib with placebo, will also be presented.

Additionally, there is an emerging role for immunotherapy in this field, Finn adds. Nivolumab (Opdivo) is also being explored in an ongoing phase III trial, which has previously shown encouraging activity. FGFR4 inhibitors are also demonstrating early promise; early data are beginning to show clinical activity in a biomarker-selected population of patients with liver cancer.

Brought to you in part by Eisai

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center